Companies · Medical Devices
Los Angeles · CA, USA · Medical Devices · founded 2021 · http://makaniscience.net/
Diligence memoA one-page analyst read on Makani Science — recommendation, valuation, rhythm, risks.→Makani Science: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Makani Science is one of 233 Medical Devices companies tracked from Los Angeles, CA, USA, on record since 2021. By capital raised it ranks in the long tail (ahead of 13% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Reinventing respiration monitoring
Makani Science is a medical device company based in Irvine, California. We have created the world's first wireless patch that can accurately and continuously monitor breathing. The company is co-founded by Dr. Michelle Khine and Dr. Michael Chu, two experts in the wearable monitoring space from the University of California, Irvine. The Makani Science system will collect unique breathing waveforms from patients in everyday environments to create the first large database of respiratory patterns associated with different diseases. Data will be collected through systems sold to our initial beachhead market, where we will help improve monitoring safety in patients being sedated for medical procedures. Our long-term goal is to combine machine learning with this database to identify and predict respiratory complications for different patient populations. We have a highly experienced team and will be FDA cleared in our beachhead market within a year.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 233 companies in Medical Devices. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 13% of sector peers (real $). Modeled value above 13% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Makani Science is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| 7D Surgical Inc. | Medical Devices | Pre-Seed | $581K | $21.4M | same sector |
| Accessible Diagnostics LLC | Medical Devices | Pre-Seed | $719K | $8.1M | same sector |
| Acera Surgical, Inc. | Medical Devices | Series A | $6.2M | $123.6M | same sector |
| ACES Diagnostics, Inc. | Medical Devices | Seed | $1.6M | $7.3M | same sector |
| Active Genomes Expressed Diagnostics Corp | Medical Devices | Pre-Seed | $250K | $2.4M | same sector |
| ACTIV Surgical, Inc. | Medical Devices | Series C | $86.6M | $239.9M | same sector |
| Acuamark Diagnostics, Inc. | Medical Devices | Series A | $20.3M | $25.6M | same sector |
| ADM Diagnostics, Inc. | Medical Devices | Pre-Seed | $620K | $22.8M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Zeit Medical Immediate stroke detection at home | Healthtech | — | — | 74% |
| Respirogen, Inc. | Other Technology | Pre-Seed | $10.6M | 74% |
| healthKERI, Inc. | Healthtech | Pre-Seed | $1.2M | 72% |
| Cognitio Labs Automating FDA-grade Traceability Requirements with Sensors and AI. | Insurance | — | — | 72% |
| Biostable Science & Engineering Inc | Other Technology | Series A | $115.6M | 72% |
| Clinical Sensors, Inc. | Biotechnology | Pre-Seed | $11.0M | 72% |
| Sound Life Sciences, Inc. | Other Technology | Pre-Seed | $10.0M | 71% |
| Breathe Technologies, Inc. | Biotechnology | Series A | $225.9M | 71% |
See where Makani Science sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Makani Science, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.